Financial Ratios Dianthus Therapeutics, Inc.

Equities

DNTH

US2528281080

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets 2024-09-06			5-day change	1st Jan Change
26.62 ^USD	-4.86%		-7.67%	+155.96%

Aug. 09	Wedbush Adjusts Dianthus Therapeutics' PT to $36 From $38, Keeps Outperform Rating	MT
Aug. 08	Dianthus Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI

66929206e9c37f.7bHL-jdoyPmLnH7KIBDuj99-dP5QDumnpu4T1nq70vw.lMaZlXsQn8va_SGtUHbW4I08OrEWRpvf4o9igUiDlr-IhK2sRTySv_jdGQ

Published financial data: DIANTHUS THERAPEUTICS, INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2021	2022	2023
Revenues	1.48M	6.42M	2.83M
Total Revenues	1.48M	6.42M	2.83M
Gross Profit	1.48M	6.42M	2.83M
Selling General & Admin Expenses, Total	1.96M	6.74M	18.16M
R&D Expenses	12.61M	29.38M	32.84M
Other Operating Expenses, Total	14.56M	36.12M	51M
Operating Income	-13.09M	-29.7M	-48.17M
Interest And Investment Income	3K	1.14M	4.76M
Net Interest Expenses	3K	1.14M	4.76M
Currency Exchange Gains (Loss)	-26K	136K	-85K
Other Non Operating Income (Expenses)	-	-52K	-60K
EBT, Excl. Unusual Items	-13.11M	-28.48M	-43.56M
EBT, Incl. Unusual Items	-13.11M	-28.48M	-43.56M
Earnings From Continuing Operations	-13.11M	-28.48M	-43.56M
Net Income to Company	-13.11M	-28.48M	-43.56M
Net Income - (IS)	-13.11M	-28.48M	-43.56M
Net Income to Common Incl Extra Items	-13.11M	-28.48M	-43.56M
Net Income to Common Excl. Extra Items	-13.11M	-28.48M	-43.56M
Per Share Items
Net EPS - Basic	-3.27	-7.1	-8.45
Basic EPS - Continuing Operations	-3.27	-7.1	-8.45
Basic Weighted Average Shares Outstanding	4.01M	4.01M	5.15M
Net EPS - Diluted	-3.27	-7.1	-8.45
Diluted EPS - Continuing Operations	-3.27	-7.1	-8.45
Diluted Weighted Average Shares Outstanding	4.01M	4.01M	5.15M
Normalized Basic EPS	-2.05	-4.44	-5.28
Normalized Diluted EPS	-2.05	-4.44	-5.28
Supplemental Items
EBITDA	-	-29.68M	-48.11M
EBITA	-13.09M	-29.7M	-48.17M
EBIT	-13.09M	-29.7M	-48.17M
EBITDAR	-	-29.44M	-47.71M
Normalized Net Income	-8.19M	-17.8M	-27.22M
Supplemental Operating Expense Items
General and Administrative Expenses	1.96M	6.74M	18.16M
Research And Development Expense From Footnotes	12.61M	29.38M	32.84M
Net Rental Expense, Total	17K	236K	394K
Stock-Based Comp., R&D Exp. (Total)	19K	416K	897K
Stock-Based Comp., G&A Exp. (Total)	44K	1.1M	2M
Total Stock-Based Compensation	63K	1.52M	2.9M

Fiscal Period: December	2021	2022	2023
Assets
Cash And Equivalents	7.64M	15.36M	132M
Short Term Investments	-	60.12M	41.39M
Total Cash And Short Term Investments	7.64M	75.49M	174M
Accounts Receivable, Total	1.48M	5.64M	478K
Total Receivables	1.48M	5.64M	478K
Inventory	243K	820K	2.16M
Prepaid Expenses	21K	32K	1.1M
Other Current Assets, Total	10K	53K	-
Total Current Assets	9.39M	82.03M	177M
Gross Property Plant And Equipment	33K	1.1M	897K
Accumulated Depreciation	-	-147K	-97K
Net Property Plant And Equipment	33K	956K	800K
Other Long-Term Assets, Total	30K	121K	1.15M
Total Assets	9.45M	83.11M	179M
Liabilities
Accounts Payable, Total	1.36M	1.17M	2.61M
Accrued Expenses, Total	3.99M	6.61M	6.5M
Current Portion of Leases	-	350K	417K
Unearned Revenue Current, Total	-	100K	100K
Total Current Liabilities	5.35M	8.22M	9.63M
Long-Term Leases	-	438K	168K
Unearned Revenue Non Current	-	791K	736K
Total Liabilities	5.35M	9.45M	10.54M
Preferred Stock Convertible	21.35M	118M	-
Total Preferred Equity	21.35M	118M	-
Common Stock, Total	-	-	15K
Additional Paid In Capital	143K	1.66M	258M
Retained Earnings	-17.39M	-45.87M	-89.42M
Comprehensive Income and Other	-	-161K	47K
Total Common Equity	-17.25M	-44.37M	169M
Total Equity	4.1M	73.66M	169M
Total Liabilities And Equity	9.45M	83.11M	179M
Supplemental Items
ECS Total Shares Outstanding on Filing Date	4.01M	4.01M	29.35M
ECS Total Common Shares Outstanding	4.01M	4.01M	14.82M
Book Value / Share	-4.31	-11.05	11.4
Tangible Book Value	-17.25M	-44.37M	169M
Tangible Book Value Per Share	-4.31	-11.05	11.4
Total Debt	0	788K	585K
Net Debt	-7.64M	-74.7M	-173M
Debt Equivalent Oper. Leases	136K	1.89M	3.15M
Account Code - Inventory Valuation	-	3	3
Machinery, Total	-	172K	282K
Full Time Employees	-	32	53

Fiscal Period: December	2021	2022	2023
Net Income	-13.11M	-28.48M	-43.56M
Depreciation & Amortization - CF	-	147K	355K
Depreciation & Amortization, Total	-	147K	355K
(Gain) Loss on Sale of Investments - (CF)	-	-606K	-1.42M
Stock-Based Compensation (CF)	63K	1.52M	2.9M
Change In Accounts Receivable	-1.01M	69K	754K
Change In Accounts Payable	4.92M	2.28M	661K
Change in Unearned Revenues	-	891K	-55K
Change in Other Net Operating Assets	-770K	-4.89M	3.5M
Cash from Operations	-9.9M	-29.07M	-36.86M
Capital Expenditure	-33K	-139K	-110K
Investment in Marketable and Equity Securities, Total	-	-59.68M	20.36M
Cash from Investing	-33K	-59.82M	20.25M
Short Term Debt Issued, Total	-	-	377K
Total Debt Issued	-	-	377K
Short Term Debt Repaid, Total	-	-	-377K
Total Debt Repaid	-	-	-377K
Issuance of Common Stock	-	-	5K
Issuance of Preferred Stock	15M	100M	-
Other Financing Activities, Total	-88K	-3.32M	134M
Cash from Financing	14.91M	96.68M	134M
Net Change in Cash	4.98M	7.79M	117M
Supplemental Items
Levered Free Cash Flow	-	-19.31M	-22.81M
Unlevered Free Cash Flow	-	-19.31M	-22.81M
Change In Net Working Capital	-	2.27M	-4.15M
Net Debt Issued / Repaid	-	-	0

Fiscal Period: December	2021	2022	2023
Profitability
Return on Assets	-	-40.12	-22.94
Return on Total Capital	-	-47.28	-24.69
Return On Equity %	-	-73.25	-35.92
Return on Common Equity	-	92.43	-69.97
Margin Analysis
Gross Profit Margin %	100	100	100
SG&A Margin	132.52	105.08	642.57
EBITDA Margin %	-	-462.44	-1.7K
EBITA Margin %	-886.59	-462.91	-1.7K
EBIT Margin %	-886.59	-462.91	-1.7K
Income From Continuing Operations Margin %	-888.14	-443.76	-1.54K
Net Income Margin %	-888.14	-443.76	-1.54K
Net Avail. For Common Margin %	-888.14	-443.76	-1.54K
Normalized Net Income Margin	-555.09	-277.35	-963.27
Levered Free Cash Flow Margin	-	-300.91	-807.32
Unlevered Free Cash Flow Margin	-	-300.91	-807.32
Asset Turnover
Asset Turnover	-	0.14	0.02
Fixed Assets Turnover	-	12.98	3.22
Receivables Turnover (Average Receivables)	-	1.8	0.92
Short Term Liquidity
Current Ratio	1.75	9.97	18.42
Quick Ratio	1.7	9.86	18.09
Operating Cash Flow to Current Liabilities	-1.85	-3.53	-3.83
Days Sales Outstanding (Average Receivables)	-	202.32	394.96
Long Term Solvency
Total Debt/Equity	-	1.07	0.35
Total Debt / Total Capital	-	1.06	0.35
LT Debt/Equity	-	0.59	0.1
Long-Term Debt / Total Capital	-	0.59	0.1
Total Liabilities / Total Assets	56.63	11.38	5.87
Total Debt / EBITDA	-	-0.03	-0.01
Net Debt / EBITDA	-	2.54	3.63
Total Debt / (EBITDA - Capex)	-	-0.03	-0.01
Net Debt / (EBITDA - Capex)	-	2.53	3.62
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	-	334.76	-55.96
Gross Profit, 1 Yr. Growth %	-	334.76	-55.96
EBITDA, 1 Yr. Growth %	-	-	62.11
EBITA, 1 Yr. Growth %	-	127	62.17
EBIT, 1 Yr. Growth %	-	127	62.17
Earnings From Cont. Operations, 1 Yr. Growth %	-	117.22	52.95
Net Income, 1 Yr. Growth %	-	117.22	52.95
Normalized Net Income, 1 Yr. Growth %	-	117.22	52.95
Diluted EPS Before Extra, 1 Yr. Growth %	-	117.04	-74.05
Accounts Receivable, 1 Yr. Growth %	-	281.98	-91.52
Inventory, 1 Yr. Growth %	-	237.45	162.8
Net Property, Plant and Equip., 1 Yr. Growth %	-	2.8K	-16.32
Total Assets, 1 Yr. Growth %	-	779.38	115.86
Tangible Book Value, 1 Yr. Growth %	-	157.22	-480.61
Common Equity, 1 Yr. Growth %	-	157.22	-480.61
Cash From Operations, 1 Yr. Growth %	-	193.52	26.8
Capital Expenditures, 1 Yr. Growth %	-	321.21	-20.86
Levered Free Cash Flow, 1 Yr. Growth %	-	-	18.15
Unlevered Free Cash Flow, 1 Yr. Growth %	-	-	18.15
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	-	-	38.37
Gross Profit, 2 Yr. CAGR %	-	-	38.37
EBITA, 2 Yr. CAGR %	-	-	91.87
EBIT, 2 Yr. CAGR %	-	-	91.87
Earnings From Cont. Operations, 2 Yr. CAGR %	-	-	82.28
Net Income, 2 Yr. CAGR %	-	-	82.28
Normalized Net Income, 2 Yr. CAGR %	-	-	82.28
Diluted EPS Before Extra, 2 Yr. CAGR %	-	-	60.7
Accounts Receivable, 2 Yr. CAGR %	-	-	-43.09
Inventory, 2 Yr. CAGR %	-	-	197.8
Net Property, Plant and Equip., 2 Yr. CAGR %	-	-	392.37
Total Assets, 2 Yr. CAGR %	-	-	335.69
Tangible Book Value, 2 Yr. CAGR %	-	-	212.89
Common Equity, 2 Yr. CAGR %	-	-	212.89
Cash From Operations, 2 Yr. CAGR %	-	-	92.92
Capital Expenditures, 2 Yr. CAGR %	-	-	82.57